Health News from Medical News Today: AVEO's Ficlatuzumab In Combination With Gefinitib Well Tolerated In Patients With Non-Small Cell Lung Cancer; Phase 1b Data Presented At ASCO

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. AVEO's Ficlatuzumab In Combination With Gefinitib Well Tolerated In Patients With Non-Small Cell Lung Cancer; Phase 1b Data Presented At ASCO 2 Jun 2011, 4:00 pm AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib (Iressa(TM)) in Asian subjects with non-small cell lung cancer (NSCLC). Ficlatuzumab is AVEO's lead monoclonal antibody candidate and a potent HGF/c-MET pathway inhibitor, and these results show that ficlatuzumab was well tolerated and demonstrated clinical activity in patients with NSCLC when combined with gefitinib... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.